Rituximab

Introduction Overview

Generic Name

rituximab

Brand Name

Rituxan, Riabni, Ruxience, Truxima

Dosage Form

injection for intravenous infusion (100 mg/10 mL, 500 mg/50 mL)

Drug Class

Antirheumatics, CD20 monoclonal antibodies

Pharmacokinetics

Absorption:
Rituximab is administered exclusively by intravenous infusion, bypassing the gastrointestinal tract; therefore, it is not absorbed via oral or other non-intravenous routes. The intravenous administration ensures 100% bioavailability, providing direct access into systemic circulation. Initial infusion rates and schedules influence plasma concentrations and pharmacodynamic effects.

Distribution:
After intravenous administration, rituximab exhibits a biphasic distribution pattern. It distributes primarily within the plasma and extracellular fluid compartments. Because rituximab is a large monoclonal antibody (~145 kDa), its penetration into tissues beyond the vascular and interstitial space is limited. Binding occurs to CD20-positive B lymphocytes circulating in blood and present in lymphoid tissues. The volume of distribution is consistent with blood and extracellular fluid volumes, reflecting limited tissue diffusion.

Metabolism:
Rituximab, being a protein therapeutic, undergoes catabolism primarily via reticuloendothelial system pathways akin to endogenous IgG antibodies. It is degraded by proteolytic enzymes throughout the body into small peptides and amino acids. There is no involvement of hepatic cytochromes or typical small-molecule metabolic pathways. The catabolic rate may be influenced by the extent of target-mediated drug disposition (binding to CD20-positive cells) and immune system interactions.

Elimination:
The clearance of rituximab is complex and involves both linear and nonlinear pharmacokinetics. Target-mediated elimination via binding to CD20-expressing B cells facilitates clearance through immune cell-mediated mechanisms. Additionally, nonspecific catabolism reduces circulating drug levels. The half-life is variable ranging from approximately 18 to 22 days but may be affected by disease state, tumor burden, or B-cell counts. The slow clearance supports dosing intervals that range from weekly to every few months depending on indication. Elimination does not involve renal or hepatic excretion of intact drug but relies on proteolytic degradation.

Dosage Forms

Available Dosage Forms:
Rituximab is available as a sterile injectable solution for intravenous infusion in two vial strengths:
- 100 mg/10 mL (10 mg/mL) single-dose vial
- 500 mg/50 mL (10 mg/mL) single-dose vial
This formulation contains rituximab and various inactive ingredients such as polysorbate 80, sodium chloride, and sodium citrate or other stabilizing agents depending on the specific biosimilar.

Dosages for Adults and Adolescents:
Dosing regimens vary widely depending on the indication:
- Non-Hodgkin's lymphoma (NHL): Typically 375 mg/m² intravenous infusion once weekly for 4 to 8 weeks, often combined with chemotherapy.
- Chronic lymphocytic leukemia (CLL): 375 mg/m² on day 1 of cycle 1 and 500 mg/m² on day 1 of subsequent cycles with chemotherapy.
- Rheumatoid arthritis (RA): 1000 mg intravenous infusion on days 1 and 15, combined with methotrexate; repeated every 24 weeks or as clinically indicated.
- Granulomatosis with polyangiitis (GPA) and Microscopic polyangiitis (MPA): 375 mg/m² weekly for 4 weeks or 1000 mg on days 1 and 15.
Pediatric dosing applies primarily to the Rituxan brand in selected indications, e.g., mature B-cell NHL in children older than 6 months with dosing per chemotherapy protocols.

Specific Patient Populations:
- Pediatric: Rituxan brand is approved for children aged 6 months and older for certain malignancies; biosimilars are not approved for pediatric use.
- Renal and hepatic impairment: No specific dosage adjustment is recommended due to proteolytic clearance.
- Elderly: Dose adjustments are generally not required, but tolerability and comorbidities should be monitored closely.
- Pregnancy and lactation: Use only if clearly needed; contraindicated during breastfeeding.
- Immunocompromised patients: Careful monitoring for infections; premedications may be necessary to reduce infusion reactions.

Mechanism Of Action

Rituximab is a chimeric monoclonal antibody specifically targeting the CD20 antigen, a transmembrane phosphoprotein expressed on the surface of pre-B and mature B lymphocytes, but not on stem cells or plasma cells. By binding CD20, rituximab targets B cells for destruction without affecting other immune cells.

The primary molecular mechanism involves two major pathways leading to B-cell depletion. First, rituximab binding activates the classical complement pathway through the Fc region of the antibody, leading to complement-dependent cytotoxicity (CDC). The complement cascade results in the formation of the membrane attack complex, lysing the B cell.

Second, rituximab-coated B cells are recognized by immune effector cells such as natural killer (NK) cells, macrophages, and granulocytes which mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This process involves engagement of Fc gamma receptors on effector cells that triggers phagocytosis or apoptosis of targeted B cells.

Additionally, rituximab may directly induce apoptosis of B cells by signal transduction events initiated upon CD20 crosslinking. Research suggests involvement of mitochondrial pathways and caspase activation.

Clinically, the selective elimination of CD20-expressing B cells reduces pathogenic B-cell populations responsible for malignancies like non-Hodgkin lymphoma and chronic lymphocytic leukemia, and modulates autoimmune processes in rheumatoid arthritis and vasculitis. Compared to non-targeted chemotherapies, rituximab offers targeted immunotherapy with a more favorable side effect profile and improved outcomes.

Several clinical studies and trials have demonstrated that rituximab’s selective B-cell depletion leads to durable responses, reduced tumor burden, and clinical remission in autoimmune diseases with sustained effects due to prolonged B-cell suppression.

Pharmacological Actions

Monoclonal antibody targeting CD20 antigen on B lymphocytes.
Induces complement-dependent cytotoxicity (CDC) to lyse B cells.
Mediates antibody-dependent cellular cytotoxicity (ADCC) via immune effector cells.
Directly induces apoptosis in CD20-positive B cells.
Selective depletion of malignant and autoreactive B-cell populations.
Modulation of autoimmune responses through B-cell suppression.
Used as immunotherapy for hematologic malignancies and autoimmune diseases.
Reduces inflammatory processes by lowering pathogenic B-cell activity.

Therapeutic Or Clinical Uses

Treatment of Non-Hodgkin's lymphoma in adults, either as monotherapy or with chemotherapy.
Management of chronic lymphocytic leukemia (CLL) in combination with fludarabine and cyclophosphamide.
Therapy for moderate to severe rheumatoid arthritis when combined with methotrexate, particularly after inadequate response to TNF inhibitors.
Treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in adults in combination with glucocorticoids.
Treatment of mature B-cell Non-Hodgkin's lymphoma and acute B-cell leukemia in children aged 6 months and older (Rituxan brand).
Management of GPA and MPA in children aged 2 years and older (Rituxan brand).
Moderate to severe pemphigus vulgaris treatment in adults (Rituxan brand).
Off-label uses may include other autoimmune diseases and certain lymphoproliferative disorders.

Side Or Adverse Effects

Infusion-related reactions including fever, chills, rash, and dyspnea.
Increased risk of infections, including bacterial, viral (notably HBV reactivation), and fungal infections.
Cytopenias such as neutropenia, leukopenia, anemia, and thrombocytopenia.
Fatigue, malaise, and body aches.
Nausea and gastrointestinal disturbances including diarrhea.
Hypotension or hypertension during infusion.
Severe skin and mucous membrane reactions including rash, blistering, and peeling.
Tumor lysis syndrome with associated metabolic abnormalities in patients with high tumor burden.
Potential cardiac adverse events including chest pain, arrhythmias, or myocardial infarction.
Renal impairment or kidney failure associated with tumor lysis or drug effects.
Progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection.
Swelling or edema and muscle spasms.
Mouth sores and upper gastrointestinal inflammation, especially in pediatric patients.
Low potassium levels (hypokalemia) documented in some cases.
More frequent upper respiratory tract infections.

Precautions

Monitor for infusion reactions; premedication with corticosteroids, acetaminophen, and antihistamines recommended.
Screen for hepatitis B virus (HBV) infection prior to initiation, with monitoring and prophylaxis if indicated.
Avoid live vaccines during treatment and until immune recovery.
Closely monitor blood counts, renal and hepatic function throughout therapy.
Use caution in patients with a history of cardiac disease or arrhythmias; monitor cardiac function during and after infusion.
Pregnancy: Use effective contraception during and for 12 months after treatment; pregnancy testing advised before initiation.
Do not breastfeed during treatment and for 6 months after last dose.
Patients with active infections or immunodeficiency require careful assessment before therapy.
Be alert for symptoms of tumor lysis syndrome in patients with high tumor burden; initiate prophylactic measures as needed.
Observe for signs of serious skin reactions and discontinue therapy if severe reactions occur.
Adjust infusion rates or discontinue infusion with severe adverse reactions.
Careful patient selection in pediatric populations; biosimilars not approved for children.
Regularly assess for new or worsening neurological symptoms suggestive of PML.
Monitor for signs and symptoms of serious infections during and after treatment.
Avoid concomitant use with other immunosuppressants without adequate monitoring.

Warnings

Boxed Warning: Risk of fatal infusion-related reactions; patients should be monitored closely during infusion.
Boxed Warning: Risk of severe mucocutaneous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Boxed Warning: Hepatitis B virus reactivation can lead to fulminant hepatitis, hepatic failure, and death.
Boxed Warning: Progressive multifocal leukoencephalopathy (PML), a rare, often fatal brain infection reported in treated patients.
Severe infections including bacterial, fungal, and viral infections may be life-threatening.
Tumor lysis syndrome has been observed; monitoring and prophylaxis are critical in high-risk patients.
Infusion reactions are common and can be severe; must have immediate medical intervention available.
Potential cardiac events including arrhythmias and myocardial infarction; cardiac monitoring is recommended in high-risk individuals.
Renal toxicity, including acute renal failure associated with tumor lysis syndrome, documented in some cases.
Severe bowel complications, such as obstruction or perforation, can occur when combined with chemotherapy.
Avoid live vaccinations during treatment; potential vaccine failure and infection risk exist.
Discontinue rituximab if severe or life-threatening reactions occur.
Post-treatment immunosuppression may increase risk of opportunistic infections.
Pregnancy and breastfeeding carry significant risks; strict precautions necessary.
Risk of secondary malignancies has not been fully determined; long-term monitoring advised.

Contraindication

Known hypersensitivity to rituximab or any component of the formulation, including murine proteins.
Active severe infections at the time of initiation of therapy.
Active hepatitis B virus infection; use contraindicated due to risk of reactivation.
Prior severe infusion reactions to rituximab leading to life-threatening reactions or anaphylaxis.
Use in children less than 6 months of age for B-cell NHL or B-AL (not approved).
Use in children under 2 years for granulomatosis with polyangiitis and microscopic polyangiitis (not approved).
Concurrent administration with live vaccines is contraindicated.
Patients with uncontrolled cardiac arrhythmias or recent myocardial infarction should avoid therapy unless benefits outweigh risks.
Known severe immunodeficiency states unless managed appropriately.
Pregnancy unless clearly necessary with risk-benefit consideration.

Drug Interactions

Concomitant use with Tumor Necrosis Factor (TNF) inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab) can increase immunosuppression and infection risk.
Disease Modifying Anti-Rheumatic Drugs (DMARDs) such as methotrexate, leflunomide, and sulfasalazine may enhance immunosuppressive effects and risk of toxicity.
Chemotherapy agents, notably cisplatin, can have additive hematologic toxicities and increased risk for infusion reactions.
Live vaccines should be avoided due to risk of vaccine-induced infection under rituximab-induced immunosuppression.
Potential interaction with drugs metabolized by immune system-modulated pathways is minimal since rituximab is not metabolized by cytochrome P450 enzymes.
Immunoglobulin products may interfere with antibody-dependent mechanisms; coadministration requires clinical consideration.
Concomitant corticosteroids may mitigate infusion reactions but increase infection risk.
Interactions with herbal supplements affecting immune function (e.g., Echinacea, St. John's Wort) are theoretically possible and warrant caution.
Vaccination efficacy, particularly with protein or conjugate vaccines, may be reduced following rituximab therapy.
Concurrent administration with other biologics may augment immunosuppression and increase adverse events.
Rituximab may reduce peripheral B-cell counts, potentially altering response to subsequent biological therapies.
Avoid concomitant use with other agents that prolong QT interval or affect cardiac conduction without cardiac monitoring.
Interaction with blood glucose lowering agents is not well documented but clinical monitoring advised due to general illness effect.
No significant interaction with acetaminophen or antihistamines used as premedications.
No known clinically significant interactions with common medications like aspirin or NSAIDs.

Preparations Of The Drug

Rituxan (rituximab) by Genentech and Biogen; intravenous infusion solutions at 100 mg/10 mL and 500 mg/50 mL vial strengths.
Truxima (rituximab-abbs) by Celltrion, Inc.; biosimilar injectable infusion solution identical in strength and use to Rituxan.
Ruxience (rituximab-pvvr) by Pfizer Ireland Pharmaceuticals; biosimilar intravenous infusion preparation at 10 mg/mL concentration.
Riabni (rituximab-arrx) by Amgen, Inc.; injectable intravenous infusion biosimilar available in single-dose vials.
Formulations contain rituximab or its biosimilar with excipients such as polysorbate 80, sodium chloride, sodium citrate dihydrate, citrate buffers, and water for injection.
All preparations are supplied as sterile, preservative-free, single-use vials requiring dilution prior to intravenous infusion.
Rituximab formulations require storage refrigerated and must be administered under controlled medical supervision.
Premedication protocols often involve corticosteroids, acetaminophen, and antihistamines to decrease infusion reactions.
No oral, subcutaneous, or intramuscular formulations currently approved; all use is via intravenous route except Rituxan Hycela (not covered here).
Biosimilars may differ slightly in excipients but have no clinically meaningful differences in safety, purity, or potency.
Preparation for infusion includes dilution in compatible intravenous fluids such as 0.9% sodium chloride or 5% dextrose in water.
Handling requires adherence to aseptic techniques and care to avoid agitation which could denature protein structure.
Packages and patient information leaflets provide detailed preparation, administration, and storage instructions for healthcare providers.